FEMY - Femasys rises on Canada approval of directional insemination product FemaSeed
2023-04-18 09:30:06 ET
- Health Canada approved Femasys' ( NASDAQ: FEMY ) FemaSeed, a product for localized directional insemination for infertility
- The company said FemaSeed is the first-ever infertility solution aimed to deliver sperm directly to the fallopian tube where contraception occurs.
- The product is designed to be less invasive and more affordable than assisted reproduction, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), according to the company.
- For FemaSeed's availability in the rest of North America, Femasys' Founder, President and CEO Kathy Lee-Sepsick said that the company was progressing after receiving IDE approval from the U.S.tates Food and Drug Administration (FDA) in Q4 last year.
- The company is on track to complete enrollment of its de novo clinical trial of FemaSeed this year, with a potential commercial launch of the product in the U.S. in 2024, if approved.
- FEMY +5.02% to $1.15 premarket April 18
For further details see:
Femasys rises on Canada approval of directional insemination product FemaSeed